Market Shaping Accelerator’s Post

There is an identified need in the Australian Vaccine Value Chain to boost vaccine commercialisation and access. Globally there are urgent calls for international collaboration in epidemic and pandemic preparedness research from the World Health Organisation, and calls for critical reforms to the R&D ecosystem for infectious diseases from the Wellcome Trust. Responding to these issues, in May 2024, Biointelect Pty Ltd led the first-of-its-kind, invitation-only Australian Vaccine Value Chain Conference©. This event, under the guidance of an expert steering committee, brought together 217 key decision-makers from industry, academia, government, non-profits, and healthcare providers. The aim was to determine key recommendations for addressing gaps and bottlenecks within the ecosystem.   Today, we launched the Outcomes paper to the attendees of this event. This comprehensive document encapsulates insights and strategies aimed at enhancing the vaccine value chain in Australia and a first response to these international initiatives. It serves as a valuable resource for all stakeholders, providing actionable recommendations to drive innovation, collaboration, and efficiency in vaccine development and distribution. The launch marks a significant milestone in our ongoing efforts to improve public health outcomes through robust and well-coordinated vaccine initiatives. Thank you to all our sponsors, contributors and conference delegates for making this possible. Read the Full Report here - https://lnkd.in/gdbQvHN4 #CSIRO #Pfizer #InvestmentNSW #Moderna #Novavax #GSK #Sanofi #mRNAVictoria #360Biolabs #CSL #DHL #MSD #MTPConnect #SAGovernment #Vaxxas #InvestSA #TheWestmeadInstituteforMedicalResearch 

Dear connections, here is our article entitled "Novel targets and improved immunotherapeutic techniques with an emphasis on antimycosal drug resistance for the treatment and management of mycosis" published in Heliyon (IF: 3.4). Article source: https://lnkd.in/gKNpdcdk Authors: Riya Sarkar, Krishnendu Adhikary, Dr. Arundhati Banerjee, Dr.Krishnendu Ganguly, Dr. Riya Sarkar, Rumpa Dhua, Dr. Koushik Bhattacharya, Deepika Ahuja, Suchandra Pal, Dr. Rajkumar Maiti. In this review article, there has been a #trial to give details #upgradation about the current #immune #therapeutical techniques and #vaccination strategies against prevention or treatment of #mycosis as well as the difficulties related with their turn of events. There has also been a visualization in the mentioned review paper about the various assorted #drugs and their specific #target #analysis along with therapeutic interventions. #CART #antigenpresentingcell #connections #mycoses #covid19 #review Elsevier #heliyon

New publication alert! Global progress in reaching the "fifth child" with lifesaving vaccines is at all time peak. This feat could be reversed by what Dr. Yauba Saidu, MD, PhD refers to as "hidden barriers" - bottlenecks to in-country vaccine financing and procurement processes. In this scientific publication, we set the foundation for more evidence-based dialogue on how to identify and address these bottlenecks through system optimization. Enjoy the read, using this link: https://lnkd.in/ez6f3DVd

Vaccines Save Lives, But Access Is Key! In low- and middle-income countries, many individuals remain unvaccinated due to various barriers. This lack of access increases the risk of preventable diseases spreading through communities. 🌏 At DRK Pharma Solutions GmbH, we are dedicated to bridging these gaps in vaccine access through our commitment to innovative clinical research. We focus on partnerships that enhance the development of effective vaccines and ensure they meet the needs of underserved populations. Join us in our mission to enhance healthcare equity. Together, we can develop solutions that lead to the creation of life-saving vaccines for every corner of the globe. Let’s connect at the The World Vaccine Congress to explore partnership opportunities! #GlobalHealth #VaccineEquity #DRKPharmaSolutionsGmbH #InnovativeDRK #WWC2024

🌍💉 Discover the disparities in economic surplus distribution in global vaccine markets. Learn how different pricing strategies and achieving IA2030 targets can impact this distribution. #SyenzaNews #VaccineEquity #GlobalHealth #IA2030 #Pricing CTA: Join us in advocating for equitable vaccine pricing policies to ensure every child has access to life-saving vaccines. Together, we can bridge the gap in global vaccine access and create a healthier, more equitable world. 👶 https://lnkd.in/dZgZvtte

https://lnkd.in/dXEG4fmz In this commentary, Mona Nemer Canada's Chief Science Officer and one of the global leaders of the 100 Days Mission for Diagnostics, Therapeutics and Vaccines highlights our work at FIND. Where we have highlighted what needs to be done, when and how fast despite significant #challenges. Although, the global response to the second #WHO declaration of a Public Health Event of International Concern (#PHEIC) for Mpox and first ever Africa CDC declaration of a Public Health Event of Continental Security (#PHECS) has been relatively lukewarm compared with the anticipated momentum; the gaps and needs are known. As we near the mark for the first 100 days, there are lessons to be learned and an opportunity to do better by all of us!

Kerry Cullinan asking the right questions on #Gavi's African Vaccine Manufacturing Accelerator #AVMA. But she got little satisfactory answers in response to the criticism that Heather Sherwin and I also articulated in a recent PLoS Global Public Health paper which you can read here: https://lnkd.in/edEbGEQb If incentives to foster local of vaccine manufacturing are not specifically designed to deliver equity, we'll continue business-as-usual, in which market imperatives trump equitable access and health resilience in LMICs

New Publication Alert from our team: The role of real-world evidence for regulatory and public health decision-making for Accelerated Vaccine Deployment - a meeting report 📜 The COVID-19 pandemic showcased the urgency for rapid evidence generation beyond traditional clinical trials. Our latest report highlights the key outcomes from the #IABS Flanders Vaccine Real-World Evidence (RWE) Conference on leveraging RWE to expedite vaccine deployment, featuring insights from regulatory, public health, and industry leaders. 💡 Key findings include RWE's critical role in enhancing decision-making for vaccine strategies, the need for improved data quality and standardisation, and the importance of regulatory transparency and stakeholder collaboration. We would like to thank our P95 authors, Kaatje Bollaerts, Chloé Wyndham-Thomas, Michelle Rubbrecht, as well as authors from our collaborating institutes: London School of Hygiene and Tropical Medicine, U. of London, FDA, Global Vaccine Data Network – GVDN, UK Health Security Agency, Flanders Vaccine, IABS - International Alliance for Biological Standardization. Special thanks are extended to our P95 colleagues who provided support for this report Marc Baay, Wendy Hartig-Merkel, and Alejandra González. Read our report in Biologicals now: https://lnkd.in/dfu-jMzM #RealWorldEvidence #PublicHealth #VaccineDeployment #Innovation #Vaccines

Recent reports of adverse events from Covaxin and Covishield COVID-19 vaccines have once again thrown up questions about how safe the vaccines we took during the pandemic really are. What do we know about COVID-19 vaccine side effects? What does the science say? Experts break down everything you need to know.

Its been 75 days since #Mpox was declared a #PHEIC but progress remains worryingly slow. ->Still no approved rapid diagnostics that can effectively differentiate between viral clades ->Limited access to point-of-care testing in most affected regions ->Only 265,000 vaccine doses delivered to DRC despite 25,000+ suspected cases ->Critical funding shortfalls - recent UK (£9M) and EU (€20M) contributions fall far short of the estimated $600M needed Time is running out for children in the affected countries, as they continue shoudering most of the burden. We need urgent action to address these gaps before this outbreak spreads further. Many thanks International Pandemic Preparedness Secretariat for tracking our path to Day 100: https://lnkd.in/ezUEnCua #GlobalHealth #HealthEquity #Mpox #VaccineEquity #PublicHealth